Fusing innovation and biotech for a more progressive tomorrow

See The Bigger Picture in Immuno Oncology Clinical Trials


Our advanced 89Zr crefmirlimab berdoxam (CD8 ImmunoPETTM) imaging agent is aimed to enable physicians to See The Bigger Picture and accelerate the progress of immunotherapy around the world.

Join us as we reimagine a new vision and approach towards immuno oncology patient care paths. Explore more about who we are, how we innovate for tomorrow and why partnering with us will help to challenge, create and transform patient care.

CD8 ImmunoPET™ Imaging Technology

Our technology uses ‘minibody’ antibodies to scan patients head-to-toe, delivering an in-depth visual profile of immunity status, before, during and after treatment.

Discover CD8 ImmunoPET

Tomorrow’s cancer patient care paths begin here…

PET Imaging

Indication
Preclinical
IND
Phase 1
Phase 2
Phase 3
PET imaging of CD8 Cells in Oncology (89Zr crefmirlimab berdoxam)
 
 
 
 
 
PET imaging CD8 T-cells in Inclusion Body Myositis (89Zr crefmirlimab berdoxam)
 
 
 
 
 
PET Imaging CD4 T-cells trafficking in Oncology and Autoimmune diseases (89Zr-Df-IAB41M2C)
 
 
 
 
 

Optical Imaging

Indication
Preclinical
IND
Phase 1
Phase 2
Phase 3
PSMA optical imaging: Prostate Cancer (IR800-IAB2MA)
 
 
 
 
 
PSMA optical imaging: Renal Cancer (IR800-IAB2MA)
 
 
 
 
 

Discover our pipeline of next generation biotech innovations.

Read more now
scan

Meet the team striving to create, challenge and transform the future of immuno oncology patient care paths.

At ImaginAb, everything we do is underpinned by medical expertise and scientific innovation. And our people are paramount to that.

Meet the team